Mangoceuticals, Common Stock Stock Performance
| MGRX Stock | 2.37 0.14 5.58% |
The company secures a Beta (Market Risk) of 0.41, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Mangoceuticals, Common's returns are expected to increase less than the market. However, during the bear market, the loss of holding Mangoceuticals, Common is expected to be smaller as well. At this point, Mangoceuticals, Common has a negative expected return of -1.32%. Please make sure to verify Mangoceuticals, Common's jensen alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Mangoceuticals, Common performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Mangoceuticals, Common Stock has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in November 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 3.29 | Five Day Return (10.36) | Year To Date Return (42.43) | Ten Year Return (95.82) | All Time Return (95.82) |
Last Split Factor 1:15 | Last Split Date 2024-10-16 |
1 | MangoRx Receives Request for Proposal From ISFLST for New Male Enhancement Product Exclusive for the Asian Market | 08/08/2024 |
2 | MangoRx Reports 1,685 percent Increase in Shareholders Equity From December 31, 2023, to 13.8MM, and 56 percent Increase in Year-Over-Year Revenue for First Hal... | 08/15/2024 |
3 | Mangoceuticals files to sell 16.17M shares of common stock for holders | 08/16/2024 |
4 | Disposition of 800000 shares by Jacob Cohen of Mangoceuticals, Common subject to Rule 16b-3 | 08/26/2024 |
5 | Disposition of 8000000 shares by Jacob Cohen of Mangoceuticals, Common subject to Rule 16b-3 | 09/13/2024 |
6 | Mens Telehealth Companys Plans To Change Mens Wellness | 09/25/2024 |
7 | MangoRx Addresses 49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutidefor Advanced Weight Loss Treatment | 10/01/2024 |
8 | MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLITAS PART OF NASDAQ COMPLIANCE PLAN | 10/11/2024 |
9 | Contrasting Mangoceuticals The Competition | 10/15/2024 |
10 | Reviewing Mangoceuticals and Its Peers | 10/18/2024 |
11 | Mangoceuticals Enters 150,000 Promissory Note Agreement with Cohen Enterprises | 10/22/2024 |
| Begin Period Cash Flow | 682.9 K |
Mangoceuticals, |
Mangoceuticals, Common Relative Risk vs. Return Landscape
If you would invest 630.00 in Mangoceuticals, Common Stock on July 25, 2024 and sell it today you would lose (394.00) from holding Mangoceuticals, Common Stock or give up 62.54% of portfolio value over 90 days. Mangoceuticals, Common Stock is currently does not generate positive expected returns and assumes 6.5287% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than Mangoceuticals,, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Mangoceuticals, Common Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mangoceuticals, Common's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Mangoceuticals, Common Stock, and traders can use it to determine the average amount a Mangoceuticals, Common's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.202
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MGRX |
Estimated Market Risk
| 6.53 actual daily | 58 58% of assets are less volatile |
Expected Return
| -1.32 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.2 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Mangoceuticals, Common is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mangoceuticals, Common by adding Mangoceuticals, Common to a well-diversified portfolio.
Mangoceuticals, Common Fundamentals Growth
Mangoceuticals, Stock prices reflect investors' perceptions of the future prospects and financial health of Mangoceuticals, Common, and Mangoceuticals, Common fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mangoceuticals, Stock performance.
| Return On Equity | -1.08 | ||||
| Return On Asset | -0.58 | ||||
| Operating Margin | (13.05) % | ||||
| Current Valuation | 5.63 M | ||||
| Shares Outstanding | 2.4 M | ||||
| Price To Book | 0.42 X | ||||
| Price To Sales | 6.73 X | ||||
| Revenue | 731.49 K | ||||
| Gross Profit | 4.85 K | ||||
| EBITDA | (9.19 M) | ||||
| Net Income | (9.21 M) | ||||
| Total Debt | 128.68 K | ||||
| Book Value Per Share | 7.12 X | ||||
| Cash Flow From Operations | (7 M) | ||||
| Earnings Per Share | (6.45) X | ||||
| Market Capitalization | 5.83 M | ||||
| Total Asset | 1.05 M | ||||
| Retained Earnings | (11.23 M) | ||||
| Working Capital | 607.38 K | ||||
About Mangoceuticals, Common Performance
Evaluating Mangoceuticals, Common's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Mangoceuticals, Common has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Mangoceuticals, Common has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 20.26 | 18.01 | |
| Return On Tangible Assets | (8.77) | (8.33) | |
| Return On Capital Employed | (10.98) | (10.43) | |
| Return On Assets | (8.77) | (8.33) | |
| Return On Equity | (11.89) | (11.30) |
Things to note about Mangoceuticals, Common performance evaluation
Checking the ongoing alerts about Mangoceuticals, Common for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mangoceuticals, Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mangoceuticals, Common generated a negative expected return over the last 90 days | |
| Mangoceuticals, Common has high historical volatility and very poor performance | |
| Mangoceuticals, Common has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 731.49 K. Net Loss for the year was (9.21 M) with profit before overhead, payroll, taxes, and interest of 4.85 K. | |
| Mangoceuticals, Common generates negative cash flow from operations | |
| About 36.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from thelincolnianonline.com: Mangoceuticals Enters 150,000 Promissory Note Agreement with Cohen Enterprises |
- Analyzing Mangoceuticals, Common's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mangoceuticals, Common's stock is overvalued or undervalued compared to its peers.
- Examining Mangoceuticals, Common's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mangoceuticals, Common's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mangoceuticals, Common's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mangoceuticals, Common's stock. These opinions can provide insight into Mangoceuticals, Common's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Mangoceuticals, Stock Analysis
When running Mangoceuticals, Common's price analysis, check to measure Mangoceuticals, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangoceuticals, Common is operating at the current time. Most of Mangoceuticals, Common's value examination focuses on studying past and present price action to predict the probability of Mangoceuticals, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangoceuticals, Common's price. Additionally, you may evaluate how the addition of Mangoceuticals, Common to your portfolios can decrease your overall portfolio volatility.